Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Andrew dudum | Vintage Vibes

A Major Telehealth Company Will Sell Longevity Peptides That Clinical Evidence Has Not Yet Backed

Hims and Hers plans to sell sermorelin, glutathione, and NAD+ before year-end. Here is what evidence exists for the uses driving demand.

Hims & Hers’ Revenue Beat Came With a Profitability Problem

Hims & Hers’ Revenue Beat Came With a Profitability Problem

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

inkl

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims Hers Health, Inc. (NYSE:HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Insider selling tests investor confidence as Hims & Hers faces valuation pressure and shifting GLP-1 momentum.

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower following a media report revealing that the Federal Trade Commission (FTC) has been investigating the company’s business practices for over a year.

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Get all your
news in one place.

100's of premium titles.
One news app.

Kevin O'leary Criticizes Hims & Hers CEO For Anti-Israel Stance

Kevin O'Leary criticizes Hims & Hers CEO for retracting anti-Israel protest support, highlighting the challenges CEOs face in navigating sensitive politica...

Hims & Hers CEO Clarifies Support For Anti-Israel Protesters

Hims & Hers CEO Andrew Dudum clarifies stance on anti-Israel protests, denounces violence, and offers job opportunities to protesters.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Wall Street Journal

The Federal Trade Commission

Hims Hers Health

Grand View Research

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

416,975 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play